Azenta, Inc.

NASDAQ:AZTA

Medical - Instruments & Supplies

Healthcare
$48.69 -0.11%

-$0.03 today

Market cap
$2.13B
Beta
1.40
P/E (TTM)
-5.9
EPS (TTM)
-$3.87
52W Low $15.93High $41.73

Volume 0.69M

Average 1.16M

AZTA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Azenta, Inc.NASDAQ: AZTA

Accounts Receivables · Q4 FY2026 · quarter ended Sep 2026

Accounts receivables turns positive

Q4 FY2026 accounts receivables was $350K, compared with -$63.36M a year earlier. Trailing-twelve-month accounts receivables was $4.42M. Over 3 fiscal years it compounded at -49.6% a year.

Context

  • Accounts receivables amounted to 0.7% of revenue in FY2026, down 3.4 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near $350K or moves back toward the trailing-twelve-month quarterly average of $1.11M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$350K+107.8% QoQ
Last fiscal yearSep 2026
$4.42M+118.0% YoY
LTMSep 2026
$4.42M+118.0% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.6%——
1 year+118.0%——
3-year CAGR-49.6%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2026
4.42M USD
Year-over-year change
+118.0%

Accounts Receivables vs competitors

How AZTA compares with its peers on the latest reported figures

  • AZTA's LTM Sep 2026 accounts receivables of $4.42M is the 6th largest of the 10 companies compared; the peer median is $3.21M.
  • Its year-over-year change of +118.0% is the 2nd highest of 10, against a peer median of +9.6%.
  • Accounts receivables amounts to 0.7% of revenue for AZTA, versus a peer median of 0.7%.
AZTA Competitors Peer median
Accounts Receivables for AZTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$174M -19.4%-23.2%0.7%
SOLVSolventum CorporationLTM Jun 2026$169M -364.1%—2.0%
TECHBio-Techne CorporationLTM Sep 2026$45.43M -188.5%-22.7%3.7%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$8.1M +148.2%—0.3%
BLFSBioLife Solutions, Inc.LTM Mar 2026$4.84M +63.4%—4.9%
AZTAAzenta, Inc.LTM Sep 2026$4.42M +118.0%-49.6%0.7%
MLABMesa Laboratories, Inc.LTM Mar 2026$3.21M +9.6%+14.8%1.3%
NEOGNeogen CorporationLTM Aug 2026$407K -101.7%—0.0%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$0 +100.0%-0.3%0.0%
BRKRBruker CorporationLTM Jun 2026$0 +100.0%—0.0%
Peer median (excluding AZTA) $3.21M+9.6%-11.5%0.7%

Competitors are the stored peer set for AZTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Net Income2.13B(14.64M)(164.9M)(55.76M)(166.99M)
Depreciation & Amortization53.7M85.58M90.74M61.21M56.52M
Deferred Income Tax24.47M(28.74M)(15.89M)(27.04M)(5.17M)
Stock-Based Compensation10.67M9.38M14.47M20.88M12.24M
Change in Working Capital(72.73M)(29.04M)3.04M(22.84M)4.06M
Accounts Receivables(31.4M)34.46M(12.07M)(24.56M)4.42M
Inventory(66.63M)8.25M15.9M(2.67M)(8.04M)
Accounts Payables(3.93M)(14.71M)9.2M1.04M12.66M
Other Working Capital29.22M(57.04M)(9.99M)3.36M(4.99M)
Other Non-Cash Items(2.62B)(16.71M)122.28M95.73M156.84M
Operating Cash Flow(466.05M)5.83M49.74M72.18M57.51M
Capital Expenditures(77.44M)(39.44M)(37.39M)(33.86M)(30.08M)
Acquisitions (Net)2.81B(386.51M)00(11.15M)
Purchases of Investments(1.98B)(236.19M)(405.58M)(451.41M)(375.68M)
Sales of Investments705.38M1.09B667.71M394.81M328.61M
Other Investing Activities(4M)00054.5M
Investing Cash Flow1.47B431.38M224.74M(90.46M)(33.8M)
Debt Repayment(50.11M)(578K)(783K)(985K)(748K)
Common Stock Issued5.25M3.62M3.28M2.77M2.2M
Common Stock Repurchased0(838.51M)(661.7M)0(118.29M)
Dividends Paid(7.49M)0000
Other Financing Activities(10.4M)(4.99M)0(11.38M)(2.67M)
Financing Cash Flow(62.76M)(840.46M)(659.21M)(9.59M)(119.5M)
Effect of Forex Changes(180.82M)45.99M21.67M3.57M(2.58M)
Net Change in Cash755.96M(357.25M)(363.06M)(24.31M)(98.37M)
Free Cash Flow(543.48M)(33.6M)12.35M38.32M27.43M

Azenta, Inc.

NASDAQ:AZTA

Intrinsic Alpha fair value

Locked

Current Price

$48.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.